A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorInstitute of Hematology & Blood Diseases Hospital, China

About this trial

This study is a multicenter interventional research on the first-line treatment of newly diagnosed adult patients with immune thrombocytopenia (ITP) using romiplostim N01 in combination with glucocorticoids. The primary endpoint of this study is to assess the efficacy of romiplostim N01 combined with glucocorticoids in untreated newly diagnosed adult ITP patients after 6 months of administration.

The subjects will be divided into the experimental group and the control group for treatment.

Experimental group: Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle. If there is no response on the 10th day, repeat once, administered either orally or intravenously. Simultaneously, romiplostim N01 is administered at an initial dose of 3µg/kg, by subcutaneous injection, once a week, for a maximum of 6 months.

Control group: Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle. If there is no response on the 10th day, repeat once, administered either orally or intravenously.

Eligibility criteria

Qualifiers

Sign the written informed consent form before enrollment;

Age ranging from 18 to 75 years old;

Be clinically diagnosed with primary immune thrombocytopenia for less than 3 months before randomization;

Have not received splenectomy or at least one first-line ITP treatment or emergency treatment in the past;

Disqualifiers

Suffering from other hematopoietic system diseases except ITP, including but not limited to leukemia, thrombocytopenia caused by tumor treatment, myeloproliferative diseases, multiple myeloma and myelodysplastic syndrome, etc.;

Having undergone splenectomy before the first administration;

Having received ITP drug treatment (including emergency treatment) before the first administration;

Having used drugs with c-Mpl (thrombopoietin receptor) stimulating effects within 4 weeks before the first administration;

Trial design

Treatments tested in this trial

  • Dexamethasone Combined with romiplostim N01
  • Dexamethasone monotherapy

Treatment groups

129 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Institute of Hematology & Blood Diseases Hospital, China

Lead sponsor

The Second Affiliated Hospital of Kunming Medical University

Collaborator

Weifang People's Hospital

Collaborator

Shenzhen Second People's Hospital

Collaborator

The Affiliated Hospital of Qingdao University

Collaborator

Changzhi Medical College

Collaborator

Affiliated Hospital of Nantong University

Collaborator

The First People's Hospital of Yunnan

Collaborator

The First Affiliated Hospital of Bengbu Medical University

Collaborator

Suining Central Hospital

Collaborator

The Second Affiliated Hospital of Dalian Medical University

Collaborator

North China University of Science and Technology

Collaborator

Guizhou Provincial People's Hospital

Collaborator